counter-generics

With patents expiring right and left, pharmaceutical companies are looking for every possible tool to slow revenue losses. Counter-generic strategies are one method to maintain market share, however temporary. Even a period of six months when no generic versions...

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...

By Michelle Vitko,Research Analyst The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a...

By Ryan McGuire,Senior Research Analyst This is the third installment in a blog series focusing on counter-generic strategies. You can read part 1 about the patent cliff and the second part on patent litigation. Under the FDA's Modernization Act Continue...

By Ryan McGuire,Senior Research Analyst This is the second installment in a blog series focusing on counter-generic strategies. Read the first part here. Litigation is a natural response for pharmaceutical and biotechnology companies that find their...

This is the first entry in a series that will focus on countering generic competition and preserving pharmaceutical brand revenue. Much has been made about the slew of drugs that face the loss of patent protection in 2011. In all, experts estimate that $30...

Key Finding #4 from our Counter-Generics and Biosimilar Threats research: Short-term strategies are still the most popular, but line-extension tactics gaining favor. Over the past three years, short-term strategies, including litigation and defensive pricing,...

It hasn't taken the Food and Drug Administration very long to move toward enhancing its internal capabilities for the review of generic drugs following a promise to do so in an August 15 agreement struck with the generics industry. The agreement calls for the...

Cutting Edge Information’s study finds that short-term strategies are giving way to long-term strategies. Short-term strategies, such as patent litigation and defensive pricing, have been the most popular counter-generics tactics for pharmaceutical brand teams...

Brand Teams Protect Their Products with an Average of Five Distinct Strategies Successful pharmaceutical and biotechnology product teams are finding that spreading their bets across multiple strategies produces the best results, according to a new report on...